Preclinical Oncology Deal Benchmarks

Median Upfront

$32M

Range: $11M - $56M

Total Deal Value

$504M

Range: $202M - $806M

Royalty Rate

5.4% - 10.7%

Tiered up to 14.7%

Dev Milestones

$236M

Range: $96M - $375M

Model Your Deal

Market Analysis

Preclinical oncology licensing deals carry a median total deal value of $504M, with upfront payments ranging from $11M to $56M. At this stage, deal structures are heavily milestone-weighted, reflecting the significant clinical risk ahead. The recommended split allocates 6% to upfront and 94% to milestones.

The oncology landscape at the preclinical stage is characterized by high competitive intensity with numerous active programs and a rapidly evolving standard of care. Development milestones average $236M, regulatory milestones contribute $142M, and commercial milestones reach $94M. ADCs, bispecifics, and radiopharmaceuticals continue to drive premium valuations across solid and hematologic tumors.

Royalty rates for preclinical oncology deals range from 5.4% to 10.7% at the base tier, with high-tier escalation to 14.7%. Earlier-stage royalties are at the lower end of industry ranges, reflecting higher clinical risk.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the average upfront payment for preclinical oncology deals?

Preclinical oncology deals average $32M in upfront payments, ranging from $11M to $56M. The upfront allocation of 6% of total deal value reflects the clinical stage risk profile.

How are preclinical oncology deal milestones structured?

Milestones account for approximately 94% of total deal value. Development milestones ($236M) represent the largest component, followed by commercial milestones ($94M) and regulatory milestones ($142M).

What royalty rates are typical for preclinical oncology licensing?

Base royalty rates range from 5.4% to 10.7%, with tiered escalation to 9.4%-14.7% on peak sales. Rates are influenced by modality, competitive positioning, and territorial scope.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Related Benchmarks

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating

For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Phase 1 Oncology Deals

Phase 1/2 Oncology Deals

Preclinical Neurology Deals

Preclinical Immunology & Autoimmune Deals

Ready to Calculate Your Deal Terms?

Need the full deal landscape?